- Home
- AIMD vs APVO Comparison
AIMD vs APVO Comparison
Compare AIMD & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- APVO
- Stock Information
- Founded
- AIMD 1984
- APVO 2016
- Country
- AIMD United States
- APVO United States
- Employees
- AIMD N/A
- APVO N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- APVO Health Care
- Exchange
- AIMD Nasdaq
- APVO Nasdaq
- Market Cap
- AIMD 2.0M
- APVO 4.1M
- IPO Year
- AIMD N/A
- APVO N/A
- Fundamental
- Price
- AIMD $3.35
- APVO $2.96
- Analyst Decision
- AIMD
- APVO Strong Buy
- Analyst Count
- AIMD 0
- APVO 1
- Target Price
- AIMD N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- AIMD 73.5K
- APVO 6.7M
- Earning Date
- AIMD 08-04-2025
- APVO 08-07-2025
- Dividend Yield
- AIMD N/A
- APVO N/A
- EPS Growth
- AIMD N/A
- APVO N/A
- EPS
- AIMD N/A
- APVO N/A
- Revenue
- AIMD $106,207.00
- APVO N/A
- Revenue This Year
- AIMD N/A
- APVO N/A
- Revenue Next Year
- AIMD N/A
- APVO N/A
- P/E Ratio
- AIMD N/A
- APVO N/A
- Revenue Growth
- AIMD 13.38
- APVO N/A
- 52 Week Low
- AIMD $2.00
- APVO $2.81
- 52 Week High
- AIMD $5.35
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- AIMD 59.21
- APVO 33.90
- Support Level
- AIMD $2.32
- APVO $2.92
- Resistance Level
- AIMD $3.20
- APVO $3.19
- Average True Range (ATR)
- AIMD 0.25
- APVO 1.05
- MACD
- AIMD 0.05
- APVO 0.24
- Stochastic Oscillator
- AIMD 93.64
- APVO 2.23
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.